Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | XDH | P47989 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.45 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17802562 | 0.85 | CFTR (0.51) | ADORA2AXDHEGFRPI4KAPI4K2B | |
| SCHEMBL9383018 | 0.84 | XDH (0.49) | ADORA2AXDHEGFRPI4KAPI4K2B | |
| SCHEMBL27886637 | 0.84 | PI4KA (0.64) | ADORA2AXDHEGFRPI4KAPI4K2B | |
| SCHEMBL17802586 | 0.83 | YTHDC1 (0.56) | ADORA2AXDHPI4KAPI4K2BPI4K2A | |
| SCHEMBL17802576 | 0.81 | CFTR (0.63) | ADORA2AXDHPI4KAPI4K2BPI4K2A | |
| SCHEMBL28298222 | 0.81 | ADORA2A (0.58) | ADORA2AXDHEGFRPI4KAPI4K2B | |
| SCHEMBL17802560 | 0.77 | FGFR1 (0.52) | XDHPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18998147 | 0.76 | TDP1 (0.45) | ADORA2AXDHEGFRPI4KAPI4K2B | |
| SCHEMBL17815604 | 0.76 | XDH (0.41) | XDHPI4KAPI4K2BPI4K2API4KB | |
| Phenol SCHEMBL28142595 | 0.75 | FGFR1 (0.49) | ADORA2AEGFRPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | ADORA2A 2194/4885XDH 635/4885EGFR 1817/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | ADORA2A 2194/4885XDH 635/4885EGFR 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.